[CP2] Interventions For Ultra-Rare Disorders (Urds) And The Logic Of Cost Effectiveness

[CP2] Interventions For Ultra-Rare Disorders (Urds) And The Logic Of Cost Effectiveness

2015 Value in Health

Schlander, M. | Garattini, S. | Holm, S. | Kolominsky-Rabas, P. | Marshall, D. A. | Nord, E. | Persson, U. | Postma, M. | Richardson, J. | Simoens, S. | de Sola-Morales, O. | Tolley, K. | Toumi, M. | Volume: 18, Issue: 3, Pages: A6,

In many cases, medicines for ultra-rare disorders (URDs) have high acquisition costs and are associated with incremental cost per quality-adjusted life year (QALY) gained exceeding widely used benchmarks for cost effectiveness.

https://www.doi.org/10.1016/j.jval.2015.03.043